Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
signaling and angiogenesis
Question
Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
?
Question
Sorafenib, a compound that targets growth [...], should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Answer
signaling and angiogenesis
If you want to change selection, open original toplevel document below and click on "Move attachment"
Parent (intermediate) annotation
Open it Sorafenib, a compound that targets growth signaling and angiogenesis, should be reserved for patients with Child-Turcotte-Pugh class A or B cirrhosis, good performance status, and vascular, lymphatic, or extrahepatic spread of the tumor.
Original toplevel document (pdf)
owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p2712
Summary
status
not learned
measured difficulty
37% [default]
last interval [days]
repetition number in this series
0
memorised on
scheduled repetition
scheduled repetition interval
last repetition or drill
Details
No repetitions
Discussion
Do you want to join discussion? Click here to log in or create user.